Phototherapy Product Insights
In the market segmentation of phototherapy by product is divided into conventional phototherapy equipment, LED phototherapy equipment, fiberoptic phototherapy equipment, germicidal lamps, accessories. Among these, LED phototherapy devices will dominate the product segment with a 48.2% phototherapy market revenue share by 2022. LED-based light therapy treats skin diseases and problems such as fine lines, psoriasis and acne. An increase in the number of people suffering from such skin diseases is expected to drive the usage of LED-based phototherapy devices.
Additionally, studies have shown that infrared light therapy can improve and reduce fine lines and wrinkles. An increasing number of people suffering from fine lines and wrinkles is expected to aid the growth of this segment. For example, according to Pushups, LLC, approximately 60 percent of Americans feel uncomfortable with their skin due to wrinkles and other skin-related issues.
This is likely to increase the usage of LED-based phototherapy devices, thereby driving segment growth over the forecast period.
Figure 2: Phototherapy Market by Product, 2022 & 2032 (USD Billion)
Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review
Phototherapy Radiation Insights
The Phototherapy market segmentation is based on radiation is divided into ultraviolet B (UVB) and psoralen ultraviolet A (PUVA). The UVB segment accounted for the largest revenue share in 2022. The UVB segment is further divided into broadband UVB and narrowband UVB. Broadband UVB uses a wide range of UVB rays. These are usually present in the sun's rays and cannot be detected with open eyes. Narrowband UVB uses a smaller, more intense portion of UVB to treat skin conditions. This is the most common type of light therapy used these days.
Broadband UVB has historically been used, but narrowband UVB phototherapy (311 nm) is becoming more common. With each exposure, more UVB doses are administered.
The common inherited skin disorder psoriasis can vary widely in intensity and extent. There is no permanent effect of any treatment, including phototherapy. Most people with severe psoriasis can benefit from UVB. It may not be suitable for people with very pale skin or whose psoriasis has become worse in the sun. Thus, the market growth is anticipated to impact it positively.
Phototherapy Application Insights
The application-based Phototherapy market data include skin disease treatment, neonatal jaundice management, and sterilization. The dermatology application segment will dominate the market with a share in 2022. This can be attributed to increased skin diseases, such as acne and leukoplakia. For example, according to the British Journal of Dermatology, there were an estimated 117.4 billion cases of acne and 231.2 Billion cases of acne epidemics in 2019, an increase of approximately 48% compared to 1990 statistics.
Likewise, leukoplakia, a disease in which the skin loses pigmented cells, is dormant in several parts of the world. For example, India has an estimated incidence of 8.8%, while Mexico has an incidence of 2.6 - 4%, according to ResearchGate. As phototherapy has been shown to arrest/slow down the progression of leukoplakia, its use is expected to increase. Hence, the phototherapy devices market growth is positive over the forecast period owing to the abovementioned factors.
Phototherapy End User Insights
Based on end use, the phototherapy industry into clinics, hospitals, dermatology centers, and home care. The hospital segment will account for the largest revenue share in 2021. This can be attributed to the number of hospitals available across the globe. Disinfection is often used in hospitals to help treat skin diseases in patients. Hospitals have been using new digital technologies to improve treatment outcomes through high precision and better user safety.
An updated study on NB-UVB, published in June 2022, found good efficacy and safety when used to treat non-segmented leukoplakia, although some patients were classified as non-responders. Studies have shown that systemic corticosteroids, topical calcineurin inhibitors, certain antioxidants, and combination therapies have all been found to improve outcomes over phototherapy alone.
September 2022: The U.S. Food and Drug Administration (FDA) approved deucravacitinib (Sotyktu, Bristol Myers Squibb) for treating adults with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy.